Jefferies analyst Maury Raycroft believes current Eiger BioPharmaceuticals share levels offer a good entry point ahead of news from the Phase III D-LIVR endpoints in hepatitis delta virus based on FDA feedback. The analyst does not anticipate major surprises around the update and expect the outcome to be viewed positively. The announcement should give the stock a bump and add momentum to a second half of 2018 run-up that will include several key catalysts, Raycroft tells investors in a research note. He sees little downside risk in Eiger shares and keeps a Buy rating on the name with a $25 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.